Form 6-K Yatsen Holding Ltd For: May 24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
--------------
Commission File Number: 001-39703
----------
Yatsen Holding Limited
Building 35, No. 2519 East Xingang Road
Haizhu District, Guangzhou 510330
People’s Republic of China
(Address of principal executive offices)
Indicate by... (continue reading...)
Form D/A Clover Biopharmaceutical
.FormData {
color: blue;
background-color: white;
font-size: 12px;
font-family: Times, serif;
}
.FormDataR {
color: blue;
background-color: white;
font-size: 12px;
font-family: Times, serif;
text-align: right;
}
.SmallFormData {
color: blue;
background-color: white;
font-size: 10px;
font-family: Times, serif;
}
.FootnoteData {
color:... (continue reading...)
Form 8-K Aldeyra Therapeutics, For: May 24
Exhibit 99.1
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxalap Over Vehicle in Ocular Redness in Completed TRANQUILITY Trial
LEXINGTON, Mass.--(BUSINESS WIRE)--May 24,... (continue reading...)
Form 24F-2NT Invesco Senior Loan Fund For: Feb 28
X0101
24F-2NT
LIVE
0000853180
XXXXXXXX
333-121061
false
N-2
Invesco Senior Loan Fund
11 Greenway Plaza
Suite 1000
Houston
TX
X1
77046-1173
true
... (continue reading...)
Form 8-K Avalo Therapeutics, Inc. For: May 18
Exhibit 99.1Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non- Eosinophilic Asthma (NEA)•Topline results expected 4Q2022WAYNE, Pa. AND ROCKVILLE, Md., May 18, 2022 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-... (continue reading...)
More SEC Filings
View Older Stories-
Form 8-K Citi Trends Inc For: May 24
-
Form 8-K WESTINGHOUSE AIR BRAKE For: May 18
-
Form 8-K NextPlay Technologies For: May 24
-
Form 8-K AVROBIO, Inc. For: May 24
-
Form 4 RumbleOn, Inc. For: May 23 Filed by: Dixon Denmar John
-
Form 8-K SIGMA LABS, INC. For: May 24
-
Form 8-K BEST BUY CO INC For: May 24
-
Form 6-K GILAT SATELLITE NETWORKS For: May 24
-
Form 6-K Burford Capital Ltd For: May 24
-
Form 4 VOXX International Corp For: May 23 Filed by: Kahli Beat
-
Form 4 MANHATTAN BRIDGE CAPITAL For: May 23 Filed by: JACKSON MICHAEL
-
Form 253G2 East Bay Permanent Real
-
Form 8-K AUTOZONE INC For: May 24
-
Form MA/A TIAA-CREF Tuition Financ
-
Form 6-K Youdao, Inc. For: May 24
-
Form 6-K AVINO SILVER & GOLD MINE For: May 24
-
Form 6-K VIA optronics AG For: May 24
-
Form SD ABB LTD
-
Form 6-K Affimed N.V. For: May 24
-
Form 20FR12B/A IPERIONX Ltd
-
Form 6-K NetEase, Inc. For: May 24
-
Form N-CSR SIT MUTUAL FUNDS II INC For: Mar 31
-
Form 6-K Ituran Location & Contro For: May 24
-
Form N-CSR SIT U S GOVERNMENT SECUR For: Mar 31
-
Form 6-K GFL Environmental Inc. For: May 24
-
Form 6-K ATRenew Inc. For: May 24
-
Form S-8 POS NOMURA HOLDINGS INC
-
Form SC 14D9/A ANTARES PHARMA, INC. Filed by: ANTARES PHARMA, INC.
-
Form 6-K SEQUANS COMMUNICATIONS For: Dec 31
-
Form 6-K HUTCHMED (China) Ltd For: May 24
-
Form S-8 POS NOMURA HOLDINGS INC
-
Form 497AD Eagle Point Income Co
-
Form 497AD Eagle Point Credit Co
-
Form 6-K PETROBRAS - PETROLEO For: Jun 30
-
Form DEFA14A DAVITA INC.
-
Form S-8 NOMURA HOLDINGS INC
-
Form SC TO-T/A ANTARES PHARMA, INC. Filed by: HALOZYME THERAPEUTICS, INC.
-
Form 8-K iMedia Brands, Inc. For: May 24
-
Form 6-K CyberArk Software Ltd. For: May 24
-
Form SD HONDA MOTOR CO LTD
-
Form 6-K Autohome Inc. For: May 24
-
Form N-30B-2 Eagle Point Income Co For: Mar 31
-
Form D GAMING INTELLIGENCE LLC
-
Form D Big Sky Development Lend
-
Form DEFA14A Spirit Airlines, Inc.
-
Form EFFECT T-Mobile US, Inc.
-
Form EFFECT HUNTINGTON INGALLS INDUS
-
Form D HO26 Fund I, a series
-
Form 3 Kiromic Biopharma, Inc. For: Feb 14 Filed by: Reeves Karen
-
Form DEFA14A BLONDER TONGUE LABORATOR
